Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Follow-Up Questions
Qui est le CEO de MoonLake Immunotherapeutics ?
Dr. Jorge Santos Da Silva est le Chief Executive Officer de MoonLake Immunotherapeutics, il a rejoint l'entreprise depuis 2022.
Quelle est la performance du prix de l'action MLTX ?
Le prix actuel de MLTX est de $54.16, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de MoonLake Immunotherapeutics ?
MoonLake Immunotherapeutics appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de MoonLake Immunotherapeutics ?
La capitalisation boursière actuelle de MoonLake Immunotherapeutics est de $3.4B
Est-ce que MoonLake Immunotherapeutics est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 17 analystes ont établi des notations d'analystes pour MoonLake Immunotherapeutics, y compris 11 achat fort, 11 achat, 2 maintien, 0 vente et 11 vente forte
